PULM - Pulmatrix Inc logo

Pulmatrix Inc

PULM

Pulmatrix, Inc. develops inhaled therapeutic products for migraine and respiratory diseases. Its iSPERSE platform delivers small or large molecules to the lungs, while its pipeline includes treatments for chronic obstructive pulmonary disease and asthma.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$5today

Score Overview

1 Year
Scoreโ€”
Net Growth22.26%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score6.8
Net Growth80.11%
Net TrendEvery year
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth85.59%
Net Trend70%
Net Income Consistency
Rev Growth-100.00%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth83.38%
Net Trend58%
Net Income Consistency
Rev Growth-100.00%
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Pulmatrix Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. PULM does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 1.48โ€”
1 Year2025-10-23
$ 4.85-69.48%
5 Years2021-10-22
$ 14.00-89.43%
10 Years2016-10-21
$ 272.00-99.46%
All Time2014-03-21
$ 3.63K-99.96%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 4M$ 2M
2025$ 0.00-$ 5M$ 4M
2024$ 7M-$ 9M$ 9M
2023$ 7M-$ 14M$ 19M
2022$ 6M-$ 18M$ 35M
2021$ 5M-$ 20M$ 53M
2020$ 12M-$ 19M$ 31M
2019$ 7M-$ 20M$ 23M
2018$ 153K-$ 20M$ 2M
2017$ 335K-$ 18M$ 3M
2016$ 835K-$ 27M$ 4M
2015$ 1M-$ 26M$ 18M
IPO2014$ 352K-$ 24M$ 15M
PULM - Pulmatrix Inc logo

Pulmatrix Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 12M to $ 0.00 and net income went from -$ 19M to -$ 5M. Revenue increased in 3 of those 5 years; net income in every one.

Between 2015 and 2025, revenue declined from $ 1M to $ 0.00 and net income went from -$ 26M to -$ 5M. Revenue increased in 5 of those 10 years; net income in 7.

Pulmatrix Inc currently holds a 5-year HDB Score of 6.8 out of 10. How the HDB Score is calculated.

Membership

Explore PULM with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies